Eli Lilly and Company (LLY)
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
3 Unstoppable Stocks That You Can Buy and Hold for Years
The market has been in free fall of late, but if you have 10-plus investing years left, now can be an optimal time to actually pile more money into stocks. With valuations lower, it can be a cheaper time to load up on quality stocks.
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to investors.
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.
Trump drops Biden's proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a fact sheet on the rule.
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
These 5 S&P 500 Stocks Are Growing Revenue The Most Right Now
These 5 companies will have minimal impact from the tariffs and could deliver strong results in 2025.
Why April Could Be a Huge Month for Eli Lilly Stock
Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.
Why Major Pharmaceutical Stocks Tumbled on Tuesday
Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro, was largely supposed to stop last month.
